You are here: Industry Insights > Breast Cancer

News List

Zydus launches Ujvira (trastuzumab emtansine) for breast cancer treatment expresspharma
May 25, 2021
Zydus Cadila launched Trastuzumab Emtansine, an antibody-drug conjugate (ADC) biosimilar and a drug for treating both early and advanced HER2 positive breast cancer, under the brand name ‘Ujvira’.
Progress Mixed in Cancer Prevention, Early Detection Measures drugs
May 24, 2021
Cancer prevention and early detection measures show mixed progress, according to a review published online May 19 in Cancer Epidemiology, Biomarkers & Prevention.
UK cancer centre to offer breast cancer treatment at home pharmatimes
April 29, 2021
The Christie NHS Foundation Trust has become the first cancer centre in the UK to offer the treatment Phesgo, developed by Roche’s Genentech division, for breast cancer at home.
Enhertu accepted via cancer drugs fund for HER2-positive breast cancer pharmatimes
April 21, 2021
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu for use within the cancer drugs fund (CDF) for the treatment of previously-treated HER2-positive metastatic breast cancer.
Thousands to benefit from five-minute breast cancer treatment pharmatimes
April 07, 2021
NHS England is rolling out an injection that dramatically cuts the amount of time breast cancer patients spend in hospital from two and a half hours to as little as five minutes across the country, following a deal with its manufacturer Roche.
EMA validates Gilead Sciences’ application for breast cancer therapy pharmaceutical-business-review
March 31, 2021
The European Medicines Agency (EMA) has validated Gilead Sciences’ marketing authorization application (MAA) for sacituzumab govitecan-hziy (SG) to treat advanced breast cancer.
Positive Phase III Clinical Results for EirGenix's Proposed Trastuzumab Biosimilar prnasia
March 25, 2021
In a press conference today, EirGenix, Inc. announced that the Phase III clinical trial (Trial No.: EGC002, NCT03433313) of its breast cancer biosimilar, EG12014 (proposed trastuzumab biosimilar, also called EGI014), has met its primary endpoint.
NHS England breast cancer wait times are ‘deeply worrying’ pharmatimes
March 12, 2021
NHS England cancer waiting times data from January shows that all targets for breast cancer have been missed, including two week wait targets as well as 31 day and 62 day targets.
Researchers identify early changes in BRCA1-positive breast cells pharmatimes
March 10, 2021
A new study has found that BRCA1-positive breast cells appear to undergo changes before becoming cancerous, which could help identify which patients can benefit from preventative surgery.
NICE recommends routine funding for Novartis’ Kisqali pharmatimes
March 01, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended routine access to Novartis’ Kisqali in certain advanced breast cancer patients.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 26 27 Next page